© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 11, 2022
Androgen-deprivation therapy with the addition of apalutamide was effective when used in patients with high-risk biochemically relapsed prostate cancer.
Atezolizumab given post-resection did not improve patients’ with renal cell carcinoma, at increased risk for recurrence, clinical outcomes compared to placebo.
June 07, 2022
Potential biomarkers of overall survival outcomes have been identified in an exploratory post-hoc analysis of the phase 3 TITAN trial.
May 16, 2022
Neoadjuvant axitnib demonstrated significant reductions in tumor size and complexity, allowing for partial nephrectomy in a subgroup of patients with renal cell carcinoma.
February 20, 2022
NeoAvAx trial results show that neoadjuvant avelumab/axitinib may be beneficial to patients with renal cell carcinoma.
February 18, 2022
Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.